BioMarin Pharmaceutical (NasdaqGS:BMRN) Earnings Call Presentation

Acquisition Overview - BioMarin will acquire Amicus Therapeutics in an all-cash transaction for $14.50 per share, valuing Amicus' equity at approximately $4.8 billion[14] - The purchase price represents a 33% premium to Amicus' closing stock price on December 18, 2025[14] - The transaction is expected to close in Q2 2026, subject to regulatory clearance and approval by Amicus' stockholders[14] Financial Impact - The acquisition is expected to increase BioMarin's long-term revenue CAGR through 2030 and beyond[12] - It is anticipated to be accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the first 12 months after close and substantially accretive beginning in 2027[12, 28] - BioMarin is committed to deleveraging, targeting gross leverage < 2.5x within two years after close[12, 28] - The transaction will be financed through a combination of cash on hand and approximately $3.7 billion of non-convertible debt financing[14] Strategic Rationale - The acquisition expands BioMarin's position as a leader in rare diseases by adding two marketed, high-growth products[4, 12, 28] - BioMarin's global scale and manufacturing capabilities will enable more patients to benefit from Galafold and Pombiliti + Opfolda[12, 28] - The deal diversifies BioMarin's revenue mix and strengthens its commercial portfolio[5, 12, 15] Product Portfolio - Galafold, an oral therapy for Fabry disease, is projected to generate $458 million in revenue in FY'25, with a growth rate of +10-15%[19] - Pombiliti + Opfolda, a two-component therapy for Pompe disease, is projected to generate $70 million in revenue in FY'25, with a growth rate of +50-65%[24]